A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find out whether the study treatment is effective against PDAC.

NCT Number	NCT07671339
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: BeOne Medicines, Breakthrough Cancer, Elicio Therapeutics, Lustgarten Foundation
Conditions	Pancreatic Cancer
Enrollment	20 participants
Start Date	2026-06-22
Primary Completion	2028-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-26